Yang Fu

Yang Fu

Auto-generated profile, based on publicly available information

Yang Fu

Department of Hematology and Oncology National Children's Medical Center, Children's Hospital of Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YFYang Fu
Yang Fu
XZXiaohua Zhu
Xiaohua Zhu
PCPing Cao
Ping Cao
CSChen Shen
Chen Shen
XQXiaowen Qian
Xiaowen Qian
XZXiaowen Zhai
Xiaowen Zhai
Purpose: To analyze the contribution of metagenomic next-generation sequencing (mNGS) in the guidance of clinical treatment and outcomes of infection during myelosuppression among children with hematological and neoplastic diseases. Patients and Methods: The clinical data and results of mNGS assay of febrile patients suspected of infection were retrospectively collected. The characteristics of pathogenic microorganisms and clinical course of myelosuppressed children with hematological diseases were summarized. Results: Our study included 70 patients (45 males) with a median age of 5 years (range: 0.5 to 13 y). During the study period, there were 96 events of suspected infection. According to comprehensive clinical diagnosis, 73 blood infections, 43 pneumonia and 2 urinary tract infections occurred. The positive rate of mNGS was significantly higher than that of traditional microbial detection (83.3% vs 17.7%). The main pathogens detected by mNGS were Pseudomonas aeruginosa, Acinetobacter, human herpesvirus, Candida and Aspergillus. The average duration of fever was 4.9 days and 11.6 days (P < 0.05), and the average cost of anti-infection treatment was RMB ¥ 28,077 and 39,898 (P < 0.05) among children received mNGS within 48 hours and more than 48 hours after the onset of infection symptoms. Conclusion: mNGS contributes to clinical management of children with infection during myelosuppression, especially among patients with negative traditional microbial detection. Early implementation of mNGS in children with symptoms has a tendency to reduce the time of infection, fever and the cost of treatment.

27 August 2024 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
PCPing Cao
Ping Cao
XZXiao Zhang
Xiao Zhang
YFYang Fu
Yang Fu
HWHongsheng Wang
Hongsheng Wang
YYYi Yu
Yi Yu
XZXiaowen Zhai
Xiaowen Zhai
X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia (XMEN) is an extremely rare inborn error of immunity (IEI) caused by X-linked recessive inheritance and loss-of-function mutations in the MAGT1 gene, resulting in magnesium ion channel defects. This article reports 2 cases of systemic EBV-positive T-cell Lymphoma of childhood (SETLC) associated with XMEN, which have not been reported before. Whole exome sequencing (WES) in their family revealed previously unreported MAGT1 gene mutations (c.77T>C, p.I26T; c.956-957del: p.Ser319Tyrfs) inherited from their mothers. These mutations expand the spectrum of gene mutations in XMEN disease. The importance of genetic testing for MAGT1 mutations in the initial diagnosis of SETLC was emphasized. We also review the literature on this uncommon IEI.

22 July 2025 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YFYang Fu
Yang Fu
LJLing Jin
Ling Jin
YDYanlong Duan
Yanlong Duan
JYJing Yang
Jing Yang
YLYing Liu
Ying Liu
XZXiaowen Zhai
Xiaowen Zhai
Background: China-Net Childhood Lymphoma (CNCL) group B-NHL-2017 study is a prospective multi-center study in China, with the purpose of standardizing the diagnosis and treatment of childhood lymphoma, and improving the prognosis. Methods: From May 2017 to June 2023, 20 centers participated in the diffuse large B-cell lymphoma (DLBCL) study. The clinical data were analyzed to summarize the clinical characteristics, treatment response and outcome. The primary endpoint was 5-year event-free survival (EFS). The trial is registered with the Chinese Clinical Trial Registry (ChiCTR1800020067). Results: A total of 138 children and adolescents were enrolled, including 101 males and 37 females. The median age of disease diagnosis was 9.0 years (range: 2.3–15.5 years). The range of follow-up time was 17 d–6.0 years. A total of 12 events occurred in this study, including 7 deaths. of which 4 patients died of disease and chemotherapy comorbidities (severe infection, septic shock, etc.), 1 died of disease progression (enlargement of the primary tumor and tumor metastasis), 1 died of recurrence, and 1 died of severe pneumonia in the third year after completing all chemotherapy courses. Recurrence occurred in 6 (4.3%) patients at 14.9 months (range: 4.4–32.6 months) after initial treatment. The 5-year overall survival (OS) was 90.7 ± 5.0% and the 5-year EFS was 85.5 ± 5.4%. Based on Cox regression analysis, no Rituximab during treatment is an independent risk factor for mortality in patients with DLBCL. Conclusion: The efficacy of CNCL-B-NHL-2017 protocol in the treatment of DLBCL in children and adolescents is close to results of international studies.

25 April 2025 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
XZXiao Zhang
Xiao Zhang
YFYang Fu
Yang Fu
HWHongsheng Wang
Hongsheng Wang
XZXiaohua Zhu
Xiaohua Zhu
YYYi Yu
Yi Yu
XZXiaowen Zhai
Xiaowen Zhai
In children with leukemia, cerebral venous sinus thrombosis (CVST) has a significant incidence and mortality rate, which may interfere with the chemotherapy process and lead to long-term neurological complications. However, large studies and population-based data on CVST in children are scarce. This study aims to characterize pediatric CVST associated with pegaspargase (PEG-ASP) and evaluate the significance of magnetic resonance venography (MRV) screening following induction remission in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). We present a retrospective cohort of a total of 27 children with CSVT and ALL/LBL. The study covers a 4-year period for MRV screening following induction remission and an 8-year comparison period, involving 716 children treated at the Department of Hematology, Children's Hospital of Fudan University. The detection rate of CVST significantly increased after MRV screening (8.4% vs. 1.6%, p < 0.01). Over half (58%) of the CVST cases were asymptomatic. Male (84% vs. 52%, p = 0.008), immune subtype of T (37% vs. 10%, p = 0.001) and higher initial platelet counts (196.25 ± 140.67 vs. 112.49 ± 115.62, p = 0.02) patients were more likely to develop CVST. The common symptoms were headache (56%), seizures (31%), vomiting (13%), lethargy (13%), coma (6%), hallucinations (6%), and schizophrenia (6%). Symptomatic patients had a higher likelihood of transverse sinus involvement (75% vs. 9%, p = 0.006). Asymptomatic patients had shorter treatment durations (25.5 ± 16.7 weeks vs. 51.6 ± 25.8 weeks, p = 0.02) and fewer long-term complications (50% vs. 0%, p = 0.02). Thromboelastographic amplitude values at 30 minutes after maximum amplitude were significantly higher in symptomatic patients (49.4 ± 13.2 vs. 35.1 ± 8.3, p = 0.01). This study highlights a significant incidence of PEG-ASP-related CVST in children, with MRV screening revealing a notably higher detection rate than previously reported. Most cases were asymptomatic, which demonstrated better prognoses, emphasizing the importance of MRV for early CVST diagnosis after induction remission in ALL/LBL. * These authors contributed equally and share the first authorship. Received: 09 December 2024 Accepted: 04 April 2025 Article published online: 25 April 2025 © 2025. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

18 May 2026 in European Journal of Haematology
Verified
Journal Article
Closed access
WOWenxin Ou
Wenxin Ou
YYYi Yu
Yi Yu
XZXiaohua Zhu
Xiaohua Zhu
JJJunye Jiang
Junye Jiang
PCPing Cao
Ping Cao
XZXiaowen Zhai
Xiaowen Zhai

23 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
YFYang Fu
Yang Fu
ZHZhongping Huang
Zhongping Huang
HWHongsheng Wang
Hongsheng Wang
XZXiaohua Zhu
Xiaohua Zhu
PCPing Cao
Ping Cao
XZXiaowen Zhai
Xiaowen Zhai
Background Aplastic anemia (AA) is a serious hematopoietic system disease in children. Although there is no standard treatment scheme for acquired non-severe aplastic anemia (NSAA) at present, cyclosporine (CsA) has always been the most commonly used first-line treatment drug for children NSAA. The number of children with AA is large in China. This study aimed to explore the effect, safety and prognosis analysis of CsA on Chinese children with acquired NSAA. Methods The clinical data of children with acquired NSAA who were diagnosed in the affiliated pediatric hospital of Fudan University from December 2010 to June 2023 and whose initial treatment was mainly oral CsA treatment (excluding the use of anti-thymocytes/anti-lymphocyte globulin) were analyzed. Results A total of 40 NSAA patients were enrolled, including 24 males and 16 females, with a median age of 7.0 years (2.5–16.5 years). Among them, 5 cases (12.5%) were blood transfusion dependent, including 1 case of red blood cell (RBC) dependence, 1 case of platelet (Plt) dependence, and 3 cases of both RBC and Plt dependence. Complete remission (CR) was achieved in 9 patients (22.5%), partial remission (PR) in 21 patients (52.5%), and none remission (NR) in 10 patients (25.0%). In PR patients, 5 patients progressed during treatment, and received hematopoietic stem cell transplantation (HSCT), 4 patients underwent hematopoietic reconstitution, and 1 patient died after transplantation; Among 10 NR patients, 4 patients progressed to SAA, of which 2 patients were still treated with oral medicine, and the other 2 patients were treated with HSCT for disease progression 2 and 4 years after treatment (1 patient died of viral brainstem encephalitis combined with sepsis after transplantation); One NR patient died of severe agranulocytosis; The other 5 cases were relatively stable after CsA treatment. The RBC count in CR group and PR group was significantly higher than that in NR group (P < 0.01 and P < 0.05, respectively). Hemoglobin (Hb) in CR group and PR group was higher than that in NR group (P < 0.05). Plt count in CR group was higher than that in NR group (P < 0.05). The average dosage of CsA in NR group was significantly higher than that in CR group (P < 0.05). The peak plasma concentration of CsA in NR group was significantly higher than that in CR group (P < 0.05). The increase of white blood cell (WBC) in CR patients and PR patients after 60 days of CsA treatment was higher than that in NR patients (P < 0.01). The Plt count of CR patients was higher than that of CR and PR patients (P < 0.01). There was no significant difference in WBC, ANC, absolute reticulocyte count (ARC), cellular immune function and CsA blood grain concentration at diagnosis among CR, PR and NR patients, and there was no difference in the increased values of ANC, RBC, Hb and ARC at 60 days after treatment. Conclusions CsA is an effective drug for the treatment of acquired NSAA in children, with good safety under therapeutic drug monitoring (TDM). The efficacy is related to the levels of RBC, Hb and Plt at the time of diagnosis and the response of WBC and Plt at 60 days after treatment.